Evidence map›Paper›PMID 30567575›Full record

ArticleCell communication and signaling : CCS2018

C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation.

Sara Ortiz-Rivero, Cristina Baquero, Luis Hernández-Cano, Juan José Roldán-Etcheverry, Sara Gutiérrez-Herrero, Cristina Fernández-Infante, Víctor Martín-Granado, Eduardo Anguita, José María de Pereda, Almudena Porras and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. C3G Protein, a New Player in Glioblastoma.International journal of molecular sciences · 2021
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sara Ortiz-RiveroInstituto de Biología Molecular y Celular del Cáncer (IMBCC), Universidad de Salamanca-CSIC, Salamanca, Spain.
Cristina BaqueroDepartamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Luis Hernández-CanoInstituto de Biología Molecular y Celular del Cáncer (IMBCC), Universidad de Salamanca-CSIC, Salamanca, Spain.
Juan José Roldán-EtcheverryServicio de Hematología y Hemoterapia, Hospital Clínico San Carlos, IdISSC, Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
Sara Gutiérrez-HerreroInstituto de Biología Molecular y Celular del Cáncer (IMBCC), Universidad de Salamanca-CSIC, Salamanca, Spain.
Cristina Fernández-InfanteInstituto de Biología Molecular y Celular del Cáncer (IMBCC), Universidad de Salamanca-CSIC, Salamanca, Spain.
Víctor Martín-GranadoInstituto de Biología Molecular y Celular del Cáncer (IMBCC), Universidad de Salamanca-CSIC, Salamanca, Spain.
Eduardo AnguitaServicio de Hematología y Hemoterapia, Hospital Clínico San Carlos, IdISSC, Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
José María de PeredaInstituto de Biología Molecular y Celular del Cáncer (IMBCC), Universidad de Salamanca-CSIC, Salamanca, Spain.
Almudena PorrasDepartamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. maporras@ucm.es.
Carmen GuerreroInstituto de Biología Molecular y Celular del Cáncer (IMBCC), Universidad de Salamanca-CSIC, Salamanca, Spain. cguerrero@usal.es.ORCID 0000-0002-8747-6831
Universidad de Salamanca · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMegakaryopoiesis allows platelet formation, which is necessary for coagulation, also playing an important role in different pathologies. However, this process remains to be fully characterized. C3G, an activator of Rap1 GTPases, is involved in platelet activation and regulates several differentiation processes.

methodsWe evaluated C3G function in megakaryopoiesis using transgenic mouse models where C3G and C3GΔCat (mutant lacking the GEF domain) transgenes are expressed exclusively in megakaryocytes and platelets. In addition, we used different clones of K562, HEL and DAMI cell lines with overexpression or silencing of C3G or GATA-1.

resultsWe found that C3G participates in the differentiation of immature hematopoietic cells to megakaryocytes. Accordingly, bone marrow cells from transgenic C3G, but not those from transgenic C3GΔCat mice, showed increased expression of the differentiation markers CD41 and CD61, upon thrombopoietin treatment. Furthermore, C3G overexpression increased the number of CD41

conclusionsAll these data indicate that C3G plays a significant role in different steps of megakaryopoiesis, acting through a mechanism dependent on its GEF activity.

Indexed as

Cell DifferentiationAdipogenesisBlood PlateletsCell Line, TumorGuanine Nucleotide-Releasing Factor 2HumansMegakaryocytesPloidiesGuanine Nucleotide-Releasing Factor 2C3GDifferentiationMegakaryocyteMegakaryopoiesisPlatelet

Identifiers

PMID30567575
PMCPMC6299959
OpenAlexW2905204514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.